Gilead Sciences (GILD) FY2024 10-K Annual Report
Gilead Sciences (GILD) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Feb 28, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Gilead Sciences FY2024 10-K Analysis
Business Overview
- • Core biopharmaceutical model focused on innovative medicines for life-threatening diseases including HIV, viral hepatitis, COVID-19, cancer, inflammation
- • Continued emphasis on fixed-dose combination oral HIV therapies like Biktarvy, Genvoya, Descovy, with FDA-approved PrEP indication for Descovy highlighted this year
Management Discussion & Analysis
- • Revenue $28.8B, up 6% YoY from $27.1B, driven by HIV, Oncology, Liver Disease sales; Veklury sales declined
- • Net income $480M, down 92% YoY from $5.7B; impacted by $4.2B IPR&D impairment and $3.8B CymaBay acquisition expenses
Risk Factors
- • FDA regulatory risk from ongoing antitrust probe involving HIV drug price practices by U.S. Federal Trade Commission
- • U.S. market exposure with 70% of total product sales $20.5B concentrated in HIV products, sensitive to U.S. healthcare policy changes
Gilead Sciences FY2024 Key Financial MetricsXBRL
Revenue
$28.8B
▲ +6.0% YoY
Net Income
$480M
▼ -91.5% YoY
Operating Margin
5.8%
▼ -2227bp YoY
Net Margin
1.7%
▼ -1922bp YoY
ROE
2.5%
▼ -2233bp YoY
Total Assets
$59.0B
▼ -5.0% YoY
EPS (Diluted)
$0.38
▼ -91.6% YoY
Operating Cash Flow
$10.8B
▲ +35.2% YoY
Source: XBRL data from Gilead Sciences FY2024 10-K filing on SEC EDGAR. All figures in USD.
Other Gilead Sciences Annual Reports
Get deeper insights on Gilead Sciences
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.